Five Prime Therapeutics (FPRX) Misses Q3 EPS by 22c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($1.37), $0.22 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $5.77 million versus the consensus estimate of $7.4 million.

Cash Guidance:

Five Prime expects full-year 2018 net cash used in operating activities to be less than $135 million, which includes the previously mentioned milestone payments earned by Five Prime. Five Prime has revised its guidance and now estimates ending 2018 with approximately $265 million in cash, cash equivalents and marketable securities, an increase from its previous guidance of approximately $250 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c